Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642780 · ClinicalTrials.gov registry record · Phase 2
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
A Phase 2 study of Solid Tumor, sponsored by Klus Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT05642780: Active Phase 2 study of Solid Tumor, sponsored by Klus Pharma.
NCT05642780 is a Phase 2 study of Solid Tumor that is active but no longer recruiting, run by Klus Pharma. The registered enrollment target is 240 participants, roughly in line with the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05642780, a Phase 2 study of Solid Tumor, is active but no longer recruiting, sponsored by Klus Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.
Primary Outcome
Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG SKB264
Study Locations (20)
Other
- Flinders Medical Centre - Bedford Park
- Wollongong Hospital - Kogarah
- Algemeen Ziekenhuis Klina - Brasschaat
- Grand Hôpital de Charleroi - Site Notre-Dame - Charleroi
- Cliniques Universitaires Saint-Luc - Woluwe-Saint-Lambert
- Centre Hospitalier de l'Université de Montréal (CHUM) - Montreal
Texas
- Texas Oncology, P.A. Amarillo, TX - Amarillo
- Texas Oncology, P.A. Austin, TX - Austin
Indiana
- Community Clinical Research Center - Anderson
Kentucky
- Norton Cancer Institute - Louisville
Maryland
- Anne Arundel Medical Center (AAMC) - Annapolis
Minnesota
- UT Health East Texas - Hope Cancer Center Tyler - Tyler
New York
- Westchester Medical Center - Hawthorne
Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc. Roanoke, VA - Roanoke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05642780 still lists
NCT05642780 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05642780 names 20 study sites across 14 states, led by Other, Texas, Indiana.
Frequently Asked Questions
What is clinical trial NCT05642780 about?
NCT05642780 is a clinical study titled "SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors". The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.
What is the current status of trial NCT05642780?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2023-01-17. Estimated completion is 2027-12-31.
What conditions does trial NCT05642780 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05642780?
The interventions under investigation include: Pembrolizumab (DRUG), SKB264 (DRUG).
Who is sponsoring clinical trial NCT05642780?
This trial is sponsored by Klus Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05642780 being conducted?
This trial has 20 study locations across Indiana, Kentucky, Maryland, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05642780's enrollment target sits among peer trials
240 28th of 196 higher than 169 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI